Pathology Unit, IRCSS Sant'Orsola-Malpighi Hospital and University of Bologna.
Pathology Unit, Maggiore Hospital.
Appl Immunohistochem Mol Morphol. 2022 Jan 1;30(1):14-18. doi: 10.1097/PAI.0000000000000972.
PRAME (PReferentially expressed Antigen in MElanoma) is a tumor-associated antigen that was recently found to be expressed by malignant melanocytic lesions but not by benign ones, thus resulting useful in this diagnostic field. PRAME could also be expressed by some normal tissues and nonmelanocytic tumors, suggesting as caution should be adopted to use PRAME as a "pan-melanoma" marker for the differential diagnosis with other malignant tumors. Until now, PRAME expression was exclusively investigated through single staining with a monoclonal antibody targeting PRAME and with double staining for Melan A/PRAME found to be useful in specific diagnostic sets. Herein, we studied the expression of PRAME in 40 melanocytic lesions and 23 nonmelanocytic ones using PRAME, Melan A/PRAME, and novel double staining for HMB45/PRAME. Although our results need to be validated, they support the adoption of HMB45/PRAME, alone or in combination with PRAME and Melan A/PRAME, as a helpful marker in the diagnosis of melanocytic neoplasms with a high concordance rate between primary melanoma and corresponding metastases.
PRAME（黑色素瘤中优先表达的抗原）是一种肿瘤相关抗原，最近发现它在恶性黑色素细胞病变中表达，但在良性病变中不表达，因此在该诊断领域很有用。PRAME 也可能在一些正常组织和非黑色素细胞肿瘤中表达，因此在将 PRAME 用作与其他恶性肿瘤进行鉴别诊断的“泛黑色素瘤”标志物时应谨慎。到目前为止，PRAME 的表达仅通过针对 PRAME 的单克隆抗体进行单染色以及通过 Melan A/PRAME 进行双重染色进行了研究，发现这两种方法在特定的诊断试剂盒中很有用。在此，我们使用 PRAME、Melan A/PRAME 和新的 HMB45/PRAME 双重染色法研究了 40 个黑色素细胞病变和 23 个非黑色素细胞病变中 PRAME 的表达。尽管我们的结果需要验证，但它们支持采用 HMB45/PRAME，单独或与 PRAME 和 Melan A/PRAME 联合使用，作为诊断黑色素瘤性肿瘤的有用标志物，其在原发性黑色素瘤和相应转移瘤之间具有高一致性率。
